

Martin Carroll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5087375/publications.pdf>

Version: 2024-02-01

95
papers

3,362
citations

304743

22
h-index

155660

55
g-index

96
all docs

96
docs citations

96
times ranked

6341
citing authors

#	ARTICLE	IF	CITATIONS
1	Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 1106-1127.	9.4	12
2	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. <i>Blood</i> , 2021, 137, 812-825.	1.4	18
3	Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2688-2692.	7.2	7
4	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	56
5	Alternative splicing redefines landscape of commonly mutated genes in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	24
6	Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2021, 138, 1465-1480.	1.4	34
7	Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. <i>Cancer Genetics</i> , 2021, 256-257, 68-76.	0.4	2
8	DNA methylation-calling tools for Oxford Nanopore sequencing: a survey and human epigenome-wide evaluation. <i>Genome Biology</i> , 2021, 22, 295.	8.8	6
9	A common protein target for an uncommon subtype of AML. <i>Blood</i> , 2020, 136, 377-378.	1.4	0
10	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020, 136, 698-714.	1.4	28
11	Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL. <i>Journal of Clinical Investigation</i> , 2020, 130, 3637-3653.	8.2	30
12	Targeted detection and quantitation of histone modifications from 1,000 cells. <i>PLoS ONE</i> , 2020, 15, e0240829.	2.5	3
13	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
14	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
15	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
16	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
17	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
18	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0

#	ARTICLE	IF	CITATIONS
19	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
20	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
21	Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Advances, 2019, 3, 1581-1585.	5.2	57
22	Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discovery, 2019, 9, 1050-1063.	9.4	288
23	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer Discovery, 2019, 9, 872-889.	9.4	36
24	Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. Blood Advances, 2019, 3, 1061-1072.	5.2	42
25	Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors. Clinical Cancer Research, 2019, 25, 573-583.	7.0	8
26	Sirolinus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Investigational New Drugs, 2018, 36, 657-666.	2.6	12
27	Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells. Haematologica, 2018, 103, 959-971.	3.5	36
28	Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica, 2018, 103, 988-998.	3.5	49
29	Aberrant splicing in B-cell acute lymphoblastic leukemia. Nucleic Acids Research, 2018, 46, 11357-11369.	14.5	39
30	Targeted Enhancer Activation by a Subunit of the Integrator Complex. Molecular Cell, 2018, 71, 103-116.e7.	9.7	50
31	CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Science Translational Medicine, 2017, 9, .	12.4	116
32	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood, 2017, 129, 177-187.	1.4	138
33	DNA Methyltransferases Demonstrate Reduced Activity against Arabinosylcytosine: Implications for Epigenetic Instability in Acute Myeloid Leukemia. Biochemistry, 2017, 56, 2166-2169.	2.5	2
34	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discovery, 2017, 7, 716-735.	9.4	582
35	The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nature Medicine, 2017, 23, 1369-1376.	30.7	971
36	Microsphere-Based Assessment of DNA Methylation for AML Prognosis. Methods in Molecular Biology, 2017, 1633, 125-136.	0.9	0

#	ARTICLE	IF	CITATIONS
37	Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. American Journal of Hematology, 2017, 92, E14-E15.	4.1	10
38	Signaling mechanisms that regulate ex vivo survival of human acute myeloid leukemia initiating cells. Blood Cancer Journal, 2017, 7, 636.	6.2	7
39	Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells. Blood, 2017, 130, 717-717.	1.4	3
40	A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0153016.	2.5	10
41	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1961-1967.	2.0	30
42	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine, 2016, 22, 792-799.	30.7	322
43	A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight, 2016, 1, .	5.0	19
44	Adaptive Reactivation of Signaling Pathways As a Novel Mechanism of Resistance to JAK Inhibitors in Ph-like ALL. Blood, 2016, 128, 755-755.	1.4	4
45	Eltrombopag Modulates Reactive Oxygen Species and Decreases Acute Myeloid Leukemia Cell Survival. PLoS ONE, 2015, 10, e0126691.	2.5	33
46	Validation of DNA Methylation to Predict Outcome in Acute Myeloid Leukemia by Use of xMELP. Clinical Chemistry, 2015, 61, 249-258.	3.2	9
47	DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia. Clinical Cancer Research, 2015, 21, 1614-1620.	7.0	50
48	When cancer and immunology meet. Immunological Reviews, 2015, 263, 2-5.	6.0	0
49	Integrated Immunological Analysis of the Bone Marrow Tumor Microenvironment in Myeloproliferative Neoplasms to Determine Potential Efficacy of Immune Checkpoint Blockade. Blood, 2015, 126, 2766-2766.	1.4	0
50	A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML. Blood, 2015, 126, 2591-2591.	1.4	0
51	Microsphere-Based Multiplex Analysis of DNA Methylation in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2014, 16, 207-215.	2.8	9
52	The Oncogene eIF4E: Using Biochemical Insights to Target Cancer. Journal of Interferon and Cytokine Research, 2013, 33, 227-238.	1.2	84
53	Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia. Blood, 2013, 122, 1651-1651.	1.4	2
54	In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2672-2672.	1.4	5

#	ARTICLE	IF	CITATIONS
55	Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia. Blood, 2013, 122, 2499-2499.	1.4	1
56	Neuromedin U Peptide Activates STAT5 and S6 in a JAK-2 Dependent Manner and Promotes Erythroid Cell Growth in Primary Erythroid Progenitor Cells. Blood, 2012, 120, 1241-1241.	1.4	0
57	Angiocidin Induces Differentiation of Acute Myeloid Leukemia (AML) Cells in Vitro and Reduces Human AML Burden in the Bone Marrow of Xenotransplanted NSG Mice.. Blood, 2012, 120, 2618-2618.	1.4	0
58	Serum 2-Hydroxyglutarate Levels Predict Isocitrate Dehydrogenase Mutations and Clinical Outcome in Acute Myeloid Leukemia.. Blood, 2012, 120, 2481-2481.	1.4	0
59	ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression. Blood, 2011, 118, 405-405.	1.4	4
60	Metabolic Capability to Induce the Pasteur Effect Mediates Sensitivity of Human Leukemic Cells to Metformin. Blood, 2011, 118, 2601-2601.	1.4	0
61	Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis. Blood, 2011, 118, 2825-2825.	1.4	1
62	A Feasibility Study of Rapamycin with Hyper-CVAD Chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) and Other Aggressive Lymphoid Malignancies and Evaluation of mTOR Signaling Using Phosphoflow. Blood, 2011, 118, 4245-4245.	1.4	1
63	MiR-101 Down Regulates Neuromedin U Expression During Human Erythropoiesis and Negatively Regulates Erythroid Expansion,. Blood, 2011, 118, 3160-3160.	1.4	0
64	Intrinsic Requirement of MicroRNA In Hox-Based Leukemia Initiating Cell Maintenance. Blood, 2010, 116, 4192-4192.	1.4	4
65	Metformin for Therapeutic Intervention In Acute Myeloid Leukemia. Blood, 2010, 116, 4351-4351.	1.4	2
66	Mir-9 Is Aberrantly Expressed In MPN Patients and Accelerates Erythropoietic Cell Growth and Differentiation. Blood, 2010, 116, 1983-1983.	1.4	0
67	Ara-C Treatment of Acute Myeloid Leukemia Does Not Lead to Prolonged Enrichment of Stem Cells or a Cell Cycle Arrest. Blood, 2010, 116, 2178-2178.	1.4	0
68	Acute Myeloid Leukemia Stem Cells Cells Are Rare and Heterogeneous in Human Acute Myeloid Leukemia.. Blood, 2009, 114, 390-390.	1.4	3
69	An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: Update of 39 Enrolled Patients.. Blood, 2009, 114, 753-753.	1.4	22
70	A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).. Blood, 2009, 114, 754-754.	1.4	19
71	Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein in AML Blasts During a Clinical Trial Combining the mTOR Inhibitor Sirolimus with Mitoxantrone, Etoposide, and Cytarabine Chemotherapy.. Blood, 2009, 114, 413-413.	1.4	0
72	MicroRNA Diagnostic Signature of Myelodysplastic Syndrome.. Blood, 2009, 114, 1763-1763.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Specific MicroRNA Deregulated in Myeloproliferative Neoplasm Are Regulated by JAK2V617F and May Contribute to Aberrant Hematopoiesis.. Blood, 2009, 114, 965-965.	1.4	15
74	SHIP1 Is a Novel Tumor Suppressor in Late-Stage Myelodysplastic Syndromes and Is Silenced by Mir-210 and Mir-155.. Blood, 2009, 114, 3824-3824.	1.4	0
75	Epigenetic Signaling Is Required for HoxA9-Based Leukemic Transformation.. Blood, 2009, 114, 3966-3966.	1.4	0
76	Phosphoproteomic Analysis of Primary Acute Myeloid Leukemia Cells Reveals Redundant Roles for Src Family Kinases in AML Survival. Blood, 2008, 112, 2650-2650.	1.4	0
77	The Effects of BCR/ABL on DNA Damage and Repair Are Dependent on Apoptosis Competence. Blood, 2008, 112, 4216-4216.	1.4	0
78	A Robust Xenotransplantation Model for Acute Myeloid Leukemia. Blood, 2008, 112, 2939-2939.	1.4	0
79	Toll-Like Receptor Agonists Induce Immunogenicity and Apoptosis of Acute Myeloid Leukemia Cells.. Blood, 2007, 110, 160-160.	1.4	2
80	Systemic Inflammatory Response Syndrome (SIRS) as Predictor of Severe Sepsis (SS) in Hospitalized Patients (pts) with Hematologic Malignancies.. Blood, 2007, 110, 633-633.	1.4	1
81	A Critical BCL6-Related Feedback Loop Explains the Unusual Biological Features of Germinal Center B-Cells and Their Malignant Transformation into B-Cell Lymphomas.. Blood, 2006, 108, 224-224.	1.4	2
82	A Novel Orally Available Parthenolide Analog Selectively Eradicates AML Stem and Progenitor Cells.. Blood, 2006, 108, 237-237.	1.4	3
83	CEP-701 Is a JAK2 Inhibitor Which Attenuates JAK2/STAT5 Signaling Pathway and the Proliferation of Primary Cells from Patients with Myeloproliferative Disorders.. Blood, 2006, 108, 3594-3594.	1.4	15
84	A Predictive Model for Cytogenetic Risk Group in Elderly AML: The Penn Cytogenetic Surrogate Score (PCSS).. Blood, 2006, 108, 4446-4446.	1.4	0
85	Mitochondrial Proteome from Human Peripheral Blood Cells.. Blood, 2006, 108, 4193-4193.	1.4	0
86	BCL6 Attenuates DNA Damage Sensing in Normal and Malignant B-Cells by Directly Repressing ATR.. Blood, 2005, 106, 157-157.	1.4	4
87	CML Progenitor Cells Have Chromosomal Instability and Display Increased DNA Damage at DNA Fragile Sites.. Blood, 2005, 106, 1989-1989.	1.4	3
88	Acute Myeloid Leukemia Cells Require STAT5 for Survival.. Blood, 2005, 106, 1616-1616.	1.4	1
89	Enhanced Survival of MDS Progenitor Cells under Hypoxic Conditions.. Blood, 2005, 106, 3427-3427.	1.4	0
90	Philadelphia Chromosome (Ph ⁺) Negative, MLL-Rearranged AML Arising in a Patient Treated with Imatinib for CML.. Blood, 2005, 106, 4880-4880.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Signaling, Drugs and Apoptosis of Myeloma Cells. <i>Cancer Biology and Therapy</i> , 2004, 3, 195-196.	3.4	1
92	BCR/ABL Expression Increases the Formation of Chromosomal Translocations after DNA Damage.. <i>Blood</i> , 2004, 104, 713-713.	1.4	1
93	mTOR Activation Is Necessary for Primary AML Cells to Survive Genotoxic Stress.. <i>Blood</i> , 2004, 104, 91-91.	1.4	5
94	mTOR Inhibitors Induce Apoptosis and Inhibit Growth of Primary Adult Human ALL in Xenograft and Tissue Culture Models.. <i>Blood</i> , 2004, 104, 2748-2748.	1.4	0
95	Beyond Directed Therapeutics: Are Two Drugs Always Better than One?. <i>Cancer Biology and Therapy</i> , 2002, 1, 683-684.	3.4	0